Biologics now account for roughly 42% of total pharmaceutical sales globally, and some analysts expect them to outpace small-molecule revenues before the end of the decade. In this environment, intellectual property (IP) is the central organising principle of corporate strategy, competitive differentiation, and long-term enterprise value. For pharmaceutical executives, in-house counsel, and law partners, generating and exploiting strategic IP intelligence is invaluable.
Why biologics demand a different IP approach
Biologics are fundamentally different from small-molecule drugs in ways that directly shape IP strategy. A monoclonal antibody may contain 20,000 or more atoms folded into three-dimensional structures produced within living organisms. These structures cannot be perfectly replicated, even by the original manufacturer. This irreducible complexity creates the ‘identical copy fallacy’: a biosimilar can only ever be highly similar to its reference biologic, never chemically identical.
That biological reality raises the bar for biosimilar entry. It also opens a broad landscape of patentable subject matter:
Manufacturing process patents;
Formulation patents;
Method-of-use patents; and
Delivery device patents.
The cumulative effect of layering these protections can extend effective market exclusivity beyond statutory limits. AbbVie’s Humira portfolio illustrates this: more than 130 granted US patents kept biosimilar competition at bay for seven years after the primary composition patent expired.
Early intelligence prevents costly surprises
IP strategy must begin at the point of research prioritisation rather than the point of filing. As Gary Gustafson, PhD, a medicinal chemist and IP expert at CAS, has observed, discovery teams often invest heavily in identifying active chemical matter only to find too late that the competitive patent landscape renders their programme commercially inviable.
Early freedom-to-operate (FTO) analysis is a litmus test, enabling organisations to focus resources on viable opportunities. FTO searches should be conducted at lead development, proof-of-concept, and again following phase II trials, providing new layers of protection while reducing the risk of commercially ruinous surprises at the point of maximum sunk cost.
Collaboration, intelligence, and M&A
Effective biologics IP management requires seamless coordination across R&D, IP, outside counsel, and business development teams. Biologics sequence searching is technically demanding in ways that keyword searches cannot address, requiring iterative review and purpose-built analytical tools that can integrate sequence data, chemical modifications, and structural information.
CAS advocates a framework that emphasises early communication between R&D and IP. Organisations should conduct thorough patentability assessments upfront and deploy flexible filing strategies to balance scientific advancement with legal protectability.
Patent filings are also among the most reliable leading indicators of competitor activity, revealing pipeline priorities years before any public disclosure. This intelligence directly informs mergers, acquisitions, and licensing. Patent expirations are projected to affect approximately $300 billion in industry revenues over the next three years, and larger pharmaceutical companies collectively hold over $1 trillion in available capital for dealmaking.
In that environment, IP due diligence is the foundation on which deal valuation rests. Licensing, meanwhile, offers a targeted alternative to full acquisition, allowing parties to access specific technologies without the complexity of integrating entire asset portfolios.
Strong IP protection is essential not only for individual companies but for the broader innovation ecosystem. Studies have estimated that overriding IP protections for even 10% of drugs would reduce social welfare by $214.5 billion per year and cost 445,000 jobs over 30 years, with patients bearing 70% of the harm through reduced drug development. The case for rigorous, proactive IP intelligence is imperative to commercial success and public health.
Biologics IP strategy in practice
The biologics market rewards organisations that treat IP intelligence as a strategic asset. The science of biologics – complex, expensive to develop, impossible to perfectly replicate – creates a landscape in which protection can be extraordinarily durable, but only for those who invest in early, comprehensive, and continuously updated analysis. For IP practitioners and business leaders alike, the insight that matters most is often the one gathered before a rival discloses theirs.
